Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., May 8, 2025 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the first quarter ended March 31, 2025. "Intellia is full steam ahead and making excellent progress across its clinical programs," said Intel ...

Core Insights - Intellia Therapeutics reported significant progress in its clinical programs, including the initiation of Phase 3 studies for hereditary angioedema (HAE) and hereditary ATTR amyloidosis with polyneuropathy [2][5] - The company ended Q1 2025 with approximately $707.1 million in cash, expected to fund operations into the first half of 2027 [5][10] - Collaboration revenue decreased to $16.6 million in Q1 2025 from $28.9 million in Q1 2024, primarily due to a reduction in revenue from the AvenCell license [10][16] Operational Highlights - The first patients were dosed in the Phase 3 HAELO study for hereditary angioedema and the MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy [2][5] - Enrollment in the global Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy is progressing ahead of projections, with expectations to exceed 550 patients by year-end [9][10] - Upcoming presentations include longer-term data from the Phase 1 study of NTLA-2002 at the EAACI Congress in June 2025 [2][6] Financial Results - Cash, cash equivalents, and marketable securities decreased from $861.7 million as of December 31, 2024, to $707.1 million as of March 31, 2025 [10][18] - Research and development expenses were $108.4 million in Q1 2025, a slight decrease from $111.8 million in Q1 2024 [10][16] - The net loss for Q1 2025 was $114.3 million, compared to a net loss of $107.4 million in Q1 2024 [10][16] Upcoming Events - Intellia will participate in several conferences, including the Bank of America Securities Health Care Conference on May 13, 2025, and the EAACI Congress on June 15, 2025 [10][12]

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) is showing potential for a bullish trend following a breakout above the 50-day moving average, indicating a key level of support [1][2]. Technical Analysis - NTLA has experienced a rally of 21.5% over the past four weeks, suggesting positive momentum [2]. - The 50-day simple moving average is a critical indicator for traders, marking the initial point of an up or down trend [2]. Earnings Estimates - There have been three upward revisions in NTLA's earnings estimates for the current fiscal year, with no downward revisions, indicating strong investor confidence [3]. - The consensus estimate for NTLA has also increased, further supporting the bullish outlook [3].

Group 1 - Intellia Therapeutics, Inc. is a leading clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine [2] - The company will present its first quarter 2025 financial results and operational highlights on May 8, 2025, at 8 a.m. ET [1] - A replay of the conference call will be available on Intellia's website starting May 8, 2025, at 12 p.m. ET [1] Group 2 - Intellia aims to develop novel, first-in-class medicines that address significant unmet medical needs and advance treatment paradigms [2] - The company is expanding its CRISPR-based platform with novel editing and delivery technologies to harness the full potential of gene editing [2]

Intellia Therapeutics, Inc. (NTLA) closed the last trading session at $8.48, gaining 19.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.79 indicates a 392.8% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $27.61. While the lowest estimate of $9 indicates a 6.1% increase from the current price level, the most optimistic a ...

SAN DIEGO, April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of thoseNASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On February 11, 2025, aNASDAQ: NTLA investor filed a lawsuit ag ...

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics for alleged violations of federal securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Intellia provided false and misleading information regarding the viability of NTLA-3001, leading investors to believe that the company had reliable data on its development and marketing [2]. - It is alleged that the company's reports on timelines for future studies were not sustainable due to high costs and inefficiencies in delivery methods [2]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels [2]. Group 2: Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [3]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Intellia made false and misleading statements regarding its drug development and marketing strategies, particularly concerning NTLA-3001 [4]. - Investors who purchased Intellia's securities between July 30, 2024, and January 8, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Intellia provided investors with a false impression of having reliable information about NTLA-3001's development [4]. - It is claimed that the company's reports on timelines for future studies were unsustainable due to high costs and inefficient delivery methods [4]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels, leading to materially misleading public statements [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Intellia Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's drug development programs [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to discuss their legal rights [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Intellia [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Company Developments and Financial Impact - Intellia's complaint alleges that the company and its executives made false statements regarding the Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [4]. - On January 9, 2025, Intellia announced a strategic shift, focusing on drug candidates NTLA-2002 and nex-z, while discontinuing NTLA-3001, leading to a workforce reduction of approximately 27% [5]. - Following this announcement, Intellia's stock price fell by $1.82 per share, or 15.14%, closing at $10.20 per share on January 10, 2025 [6].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit from investors who purchased securities during a specified period, alleging misleading statements regarding the viability of its drug development programs [1][4]. Company Overview - Intellia is a genome editing company focused on developing curative therapeutics, with a notable project being NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [3]. Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability and development of NTLA-3001, including: - Misrepresentation of reliable information regarding NTLA-3001's development and marketing potential [4]. - Overly optimistic timelines for dosing and future studies that did not align with reality [4]. - Lack of capability to timely dose patients or maintain research and development for NTLA-3001 due to the challenges of viral-based editing methods [4]. - Concerns about the cost and inefficiency of viral-based editing drugs, even if NTLA-3001 was successful [4]. Impact of Company Reorganization - On January 9, 2025, Intellia announced a reorganization, prioritizing resources towards NTLA-2002 and nex-z, leading to the discontinuation of NTLA-3001. This announcement resulted in a stock price drop of over 15% [5].